These clinical studies suggest that the elevated sBCMA levels seen in patients with advanced relapsed/refractory multiple myeloma interfere with BCMA-targeting antibodies binding to BCMA on tumor cell surface and thus impair therapeutic efficacy. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.